The molecular mechanisms underlying the differentiation of interleukin 17-producing T helper cells (T H -17 cells) are still poorly understood. Here we show that optimal transcription of the gene encoding interleukin 17 (Il17) required a 2-kilobase promoter and at least one conserved noncoding (enhancer) sequence, CNS-5. Both cis-regulatory elements contained regions that bound the transcription factors RORct and Runx1. Runx1 influenced T H -17 differentiation by inducing RORct expression and by binding to and acting together with RORct during Il17 transcription. However, Runx1 also interacts with the transcription factor Foxp3, and this interaction was necessary for the negative effect of Foxp3 on T H -17 differentiation. Thus, our data support a model in which the differential association of Runx1 with Foxp3 and with RORct regulates T H -17 differentiation.
The differentiation of interleukin 17 (IL-17)-producing T helper cells (T H -17 cells) has been the subject of much attention, mainly because IL-17 and other cytokines released from T H -17 cells are important to the pathogenesis of autoimmune inflammation in both mice and humans 1-5 . In mice, T H -17 differentiation is induced by the combined activity of transforming growth factor-b (TGF-b) and IL-6 (refs. 6,7), whereas in humans, TGF-b and IL-21 (naive cells) or IL-1b (memory cells) 8, 9 have a predominant function. In both species, however, these cytokines affect IL-17 production by inducing the expression of key lineage-specific transcription factors: the orphan nuclear receptor RORgt (A002302) and a related factor, RORa 1, 8, 10 .
Studies of the transcription of genes encoding T helper type 1 (T H 1) or T H 2 cytokine such as interferon-g and IL-4, respectively, have shown that such transcription is controlled in part by cis-regulatory elements consisting of evolutionarily conserved noncoding sequences (CNS) elements located in the vicinity of the gene encoding the cytokine [11] [12] [13] . One such CNS element is also present in the Il17 locus and enhances the transcriptional activity of a minimal Il17 promoter 14 . However, the actual location of the Il17 promoter and the function of the CNS in Il17 transcription is still mostly undefined.
It has been shown that Foxp3 (A002750), the TGF-b-induced, lineage-specific transcription factor of regulatory T cells (T reg cells), also influences T H -17 differentiation. Specifically, Foxp3 physically interacts with RORgt, and this interaction considerably inhibits Il17 transcription 15 . This 'yin-yang' relationship of RORgt and Foxp3 is the probable basis of the observation that the differentiation of T H -17 cells and T reg cells is often reciprocal. The function of Foxp3 in T H -17 differentiation also suggests that one or more Runx transcription factors may influence Il17 transcription. This follows from the finding that Foxp3 also interacts with Runx1 (A000523) and such interaction is required for the negative regulation of Il2 transcription 16 . Runx proteins can regulate transcription in a context-dependent way by binding to other transcription factors to form coactivator or corepressor complexes; for example, Runx3 acts cooperatively with T-bet to promote expression of the gene encoding interferon-g and to silence Il4 in T H 1 cells 17 . In this study, we marshal evidence indicating that Il17 transcription is dependent on RORgt as well as the second factor Runx1 (and possibly Runx2), and that both factors act at promoter and enhancer regions to regulate transcription. In addition, we show that Runx1 binds to RORgt and to Foxp3 to bring about positive and negative effects on Il17 transcription.
RESULTS
The cis elements regulating Il17 transcription We initially did studies to define the promoter elements that participate in the regulation of Il17 transcription. Accordingly, we generated a series of reporter constructs containing regions upstream of the Il17 transcription start site and assessed the activity of these constructs by transfecting them into Jurkat cells, which we then stimulated with the phorbol ester PMA and ionomycin. A reporter consisting of a 2-kilobase (kb) promoter fragment containing a binding site for theregulating the Il17 promoter, we then assessed the reporter activity of Il17 promoter fragments in cells cotransfected with RORgt-expressing constructs. In the presence of RORgt, the 2-kb promoter fragment had about twofold higher luciferase activity, but the 1.1-kb fragment that contained the RORgt-binding site showed no greater luciferase activity relative to that of the 0.6-kb fragment (Fig. 1b) . To further assess the importance of RORgt in Il17 promoter activity, we assessed the reporter activity of a 2-kb promoter with a mutated RORgt-binding site. This mutated construct had much lower luciferase activity that was not reversed by cotransfection of exogenous RORgt (Fig. 1c) . These results collectively indicate that whereas RORgt regulates Il17 transcription through its promoter, other factors in addition to RORgt may also influence Il17 transcription.
We also searched for CNS elements, similar to those that act as distal upstream enhancers regulating Il4 and the gene encoding IFN-g 1, 12, 18, 19 , that regulate Il17 transcription. For this, we compared approximately 200 kb of DNA in the mouse Il17 locus with a similar sequence in the human IL17 locus using the VISTA global alignment program. We identified several CNS sites, including CNS-5 (also called CNS-2; ref. 14), which was approximately 5 kb upstream of Il17 and contained a perfect consensus binding sequence for RORgt, TGACCT ( Fig. 2a and Supplementary Fig. 1a online) . Another site, CNS-19, was approximately 19 kb upstream of Il17 and lacked a RORgtbinding sequence. To determine the function of these CNS elements in Il17 transcriptional regulation, we used a promoter-reporter strategy similar to that described above but in this case with constructs containing promoter fragments linked to CNS sequences. The reporter activity of the 2-kb promoter was much greater when linked to CNS-5, particularly in the presence of exogenous RORgt; in contrast, the reporter activity of the 2-kb promoter fragment was not enhanced when linked to CNS-19 (Fig. 2b) . In addition, in a way dependent on RORgt expression, CNS-5 also amplified the luciferase activity Figure 1 Mouse Il17 promoter activity. (a) Luciferase activity of Jurkat cells transfected with fragments (0.6 kb, 1.1 kb and 2 kb) of the mouse Il17 promoter linked to firefly luciferase reporter constructs along with a renillla luciferase vector (transfection efficiency control), allowed to 'rest' overnight, then left unstimulated (None) or stimulated for 6 h with PMA and ionomycin (PMA + iono). Results are presented relative to renilla luciferase activity. (b) Luciferase activity of Jurkat cells transfected with luciferase reporter constructs plus RORgt-expressing vector (+RORgt) or empty vector (-RORgt), allowed to 'rest' overnight, then stimulated for 6 h with PMA and ionomycin and assessed as described in a. Below, immunoblot analysis of RORgt expression in transfected Jurkat cells, detected with anti-RORg (a-RORg). (c) Luciferase activity of Jurkat cells transfected with luciferase reporter constructs containing an intact 2-kb promoter or a 2-kb promoter with a mutated RORgt-binding site, plus RORgt-expressing or empty vector, then stimulated and assessed as described in b. Data are representative of at least four (a,b) or three (c) independent experiments (mean and s.d. of triplicate transfections). induced by the shorter IL-17 promoter fragments (Fig. 2c) . However, this luciferase activity was still lower than that noted with the 2.0-kb promoter (data not shown).
To determine if the CNS-5 enhancer activity depended on RORgt, we mutated the RORgt-binding site in CNS-5. The mutated CNS-5 construct induced much less luciferase activity than its wild-type counterpart did when cotransfected with RORgt into Jurkat cells (Fig. 2d) . Moreover, luciferase activity was almost completely abolished by mutation of the RORgt-binding sites in both CNS-5 and the 2-kb promoter (Fig. 2d) . These results suggested that both the 2-kb promoter and the enhancer element CNS-5 are required for maximum Il17 transcription.
To further confirm that CNS-5 is an enhancer element, we cloned CNS-5 and CNS-19 separately into a PGL4.23 reporter vector containing a minimal irrelevant promoter. Cotransfection of the CNS-5-containing reporter and an RORgt construct into Jurkat cells resulted in a strong luciferase signal, and this signal was much lower when the RORgt-binding site in CNS-5 was mutated ( Supplementary  Fig. 1b ). In contrast, the CNS-19-containing construct showed no luciferase signal in any circumstances ( Supplementary Fig. 1b) . These results collectively provide evidence that CNS-5, but not CNS-19, is an RORgt-dependent enhancer element for Il17 transcription.
Regulation of Il17 transcription by Runx1
As noted above, the 1.1-kb promoter fragment containing the RORgtbinding site showed low reporter activity, whereas the 2-kb fragment showed much higher promoter activity. Because of this discrepancy, we analyzed the sequence located between 1.1 kb and 2 kb of the Il17 promoter and identified consensus binding sequences for several transcription factors, including STAT, Runx and Foxp factors ( Supplementary Fig. 2a online) . Of those, we focused on Runx, given published evidence that Runx family members are involved in TGF-b signaling [20] [21] [22] , T H 1 differentiation and T reg cell function 16, 17 . Accordingly, we did reporter assays with Jurkat cells cotransfected with constructs expressing Runx1 and the 2-kb Il17 promoter reporter. The presence of exogenous Runx1 amplified the luciferase signal induced by the 2-kb promoter fragment (Fig. 3a) . Cotransfection of constructs expressing Runx2 or Runx3 also amplified the luciferase activity driven by the 2-kb promoter fragment, albeit to a lesser extent than Runx1 did ( Supplementary Fig. 2b) .
In further studies, we did reporter assays with Jurkat cells transfected with promoter reporter constructs in which Runx-binding sites were mutated. Mutation of either one or both of the Runx-binding sites in the 2-kb promoter fragment led to less reporter activity and this effect was not reversed by cotransfection of an RORgt-expressing construct (Fig. 3b) . In addition, Runx1 did not increase the luciferase activity of a 2-kb promoter fragment with a mutated RORgt-binding site (Fig. 3c) . These studies thus indicate that Runx1 is important in the transcription of Il17 and that the effect of Runx1 is dependent on RORgt.
Runx1 is required for T H -17 differentiation
To define the requirement of Runx proteins in the differentiation of primary T H -17 cells, we measured the expression of Runx mRNA and protein in CD4 cells cultured in various T helper cell-polarizing conditions. Because all Runx family members were expressed in T H -17 cells ( Supplementary Fig. 3a -c online), we further evaluated the influence of each Runx protein on Il17 transcription by measuring IL-17 expression in primary T cells. We examined IL-17 expression in primary T cells ectopically expressing individual Runx proteins. Overexpression of Runx1 induced the greatest increase in IL-17 expression, and overexpression of Runx2 led to lesser but still substantial increase; in contrast, overexpression Runx3 led to only a marginal increase (Fig. 4a ). All three Runx proteins were transcriptionally active in these cells, as judged by their ability to promote the production of interferon-g ( Supplementary Fig. 4 online). As Runx1, Runx2 and Runx3 are similar in structure, it is possible that overexpression studies may not be the best way to measure their specific functions. Thus, we attenuated expression of the individual Runx proteins with small interfering RNA (siRNA). First, we confirmed that each of the designed siRNA duplexes specifically affected its target Runx transcript ( Supplementary Fig. 5a online) . We then transfected the individual Runx-specific siRNA duplexes into T cells cultured in T H -17 conditions and evaluated IL-17 expression. Silencing of Runx1 led to a much lower percentage of IL-17 + cells, whereas silencing of Runx2 had only a modest effect and silencing of Runx3 had no effect (Fig. 4b) . These results collectively indicate that although all Runx proteins are expressed in T H -17 cells, Runx1 is probably the main Runx family member involved in IL-17 expression. These results are also consistent with our reporter experiments in which Runx1 maximally enhanced the transcription mediated by the Il17 2-kb promoter fragment ( Supplementary Fig. 2b ).
To further confirm the function of Runx1 in the differentiation of primary T H -17 cells, we cultured CD4 + T cells in T H -17 polarizing conditions and transduced them with Runx1 or dominant negative Runx1 (Runx1DN) constructs tagged with green fluorescent protein (GFP) and containing an internal ribosomal entry site (IRES); the Runx1DN construct encoded a Runx1 protein lacking the carboxy-terminal transcriptional activation and inhibition domains 16 (Fig. 4c) produced IL-17 whereas the percentage of IL17-producing cells among Runx1DN-transduced cells was much lower (Fig. 4d) . Finally, we 'knocked down' endogenous Runx1 expression with a short hairpin RNA (shRNA) retroviral vector. Runx1 expression was decreased specifically by Runx1 shRNA but not by the vector containing a control hairpin; in addition, this Runx1-specific shRNA did not influence the expression of Runx2 or Runx3 (Supplementary Fig. 5b ). The proportion of IL17 + cells was lower among cells transduced with Runx1-specific shRNA than among cells transduced with the control shRNA vector (Fig. 4e) . Collectively, these results demonstrate that Runx1 is required for T H -17 differentiation.
Runx1 acts together with RORct to activate Il17
We next sought to understand the interaction between Runx1 and RORgt in T H -17 differentiation. We transduced CD4 + T cells with Runx1 or Runx1DN and cultured them with no cytokine or with IL-6 or TGF-b alone or together. In cells cultured without cytokine or with IL-6 (conditions in which endogenous RORgt is not induced), overexpression of Runx1 had no effect on IL-17 production (Fig. 5a) . However, in cells cultured with TGF-b, which can induce RORgt expression 23 , overexpression of Runx1 lead to enhanced IL-17 expression (Fig. 5a) . Thus, the greater number of IL-17-producing cells among Runx1-transduced cells cultured with TGF-b may have been due to 'collaboration' between Runx1 and RORgt. When we cultured cells in T H -17-polarizing conditions of IL-6 and TGF-b, in which large amounts of endogenous RORgt were produced, ectopic expression of Runx resulted in a much higher fraction of cells producing IL-17. To further demonstrate that Runx1 acts together with RORgt to induce IL-17 production, we overexpressed RORgt and Runx1 in T cells cultured in both T H 0 conditions (no cytokines) and T H -17 conditions. In each condition, RORgt-induced IL-17 production was further enhanced when Runx1 was coexpressed (Fig. 5b) . In contrast, RORgt-induced IL-17 production was lower when Runx1DN was coexpressed. These results collectively indicated that Runx1 acts together with RORgt to potentiate IL-17 expression and is required for the full effect of RORgt on IL-17 expression. In addition, RORgtinduced IL-17 production was also enhanced when RORgt was coexpressed with Runx2, albeit to a lesser extent than when it was coexpressed with Runx1, whereas we noted only marginal enhancement with coexpression of Runx3 ( Supplementary Fig. 6 online) .
To gain further insight into how Runx1 and RORgt regulate IL17 transcription, we did chromatin immunoprecipitation (ChIP) assays to determine if these factors bind to the Il17 promoter and/or enhancer during T H -17 differentiation. In an initial study, we used ectopically expressed Flag-tagged Runx1 and Myc-tagged RORgt and detected the binding of these two transcription factors to the Il17 promoter and enhancer with antibody to Flag (anti-Flag) or anti-Myc, respectively. Both RORgt and Runx1 showed a positive ChIP signal for the Il17 promoter and the CNS-5 enhancer region but no substantial binding to the CNS-19 region (Fig. 6a,b) . We also used anti-Runx1 and anti-RORg to examine the binding of endogenous Runx1 and RORgt to the Il17 promoter and enhancers in T H -17 cells. The Runx1-specific antibody did not cross-react with either Runx2 or Runx3 (Supplementary Fig. 3a) . Fig. 6c,d ). These results indicated that the recruitment of both RORgt and Runx1 to both promoter and enhancer regions of Il17 might be necessary for optimal activation of IL-17 expression. An alternative mechanism by which Runx1 may regulate IL-17 expression is by inducing RORgt expression. To investigate that possibility, we transduced CD4 + T cells with empty GFP vector or the GFP-tagged Runx1 or Runx1DN retrovirus construct and cultured the cells in T H -17-polarizing conditions. We sorted GFP + cells and restimulated them with anti-CD3 and anti-CD28, then measured the expression of RORgt and IL-17 by real-time RT-PCR. The expression of RORgt and IL-17 was much higher in cells transduced with Runx1 and lower in cells transduced with Runx1DN than in cells transduced with empty GFP vector (Fig. 7a) . To further confirm that finding, we transfected purified CD4 + cells with Runx1-specific siRNA or 'scrambled' siRNA (as in Fig. 4b ) and measured the expression of Runx1, RORgt and IL-17 by real-time RT-PCR at 48 h after transfection. The expression of Runx1, RORgt and IL-17 was lower, but the expression of Runx2 and Runx3 remained the same in cells transfected with Runx1-specific siRNA (Fig. 7b and data not shown) . These results provide evidence that an additional mechanism by which Runx1 regulates T H -17 differentiation is by inducing RORgt expression.
CNS-19 (

Foxp3 represses RORct-and Runx1-induced IL-17 expression
Studies have shown that TGF-b induces the expression of RORgt 23 and Foxp3 (refs. 23,24) . RORgt enhances IL-17 expression, whereas Foxp3 inhibits IL-17 expression 15 . Other studies have shown that Foxp3 physically interacts with RORgt during the regulation of IL-17 induction 15 and with Runx1 during the inhibition of IL-2 expression 16 . We therefore hypothesized that Foxp3 controls the ability of Runx1 to functionally interact with RORgt during T H -17 differentiation. To investigate that possibility, we first assessed the effect of Foxp3 on RORgt-induced IL-17 expression. We cotransduced CD4 + T cells with RORgt and Foxp3 or one of four mutant Foxp3 constructs; three Foxp3 mutants were carboxy-terminal truncations and the fourth mutant (Foxp3 329VHL) contained three point substitutions in the Runx1-binding site 16 (Fig. 8a) . We cultured the transduced cells in T H -17 or T H 0 conditions and assessed IL-17 expression. Wild-type Foxp3 suppressed RORgt-induced IL-17 expression, but the suppressive activity of Foxp3 was abrogated by substitution of its Runx1-binding site (Foxp3 329VHL) or by removal of the carboxy-terminal forkhead DNA-binding domain (Fig. 8b) . Next, we determined the effect of Foxp3 on Runx1-induced IL-17 expression. We transduced CD4 + T cells with Runx1 alone or Runx1 in combination with wildtype or mutant Foxp3 and cultured the cells in T H -17-polarizing conditions. Wild-type Foxp3 inhibited Runx1-induced IL-17 expression, but this inhibitory effect of Foxp3 was also abrogated by substitution of the Runx1-binding domain or by truncation of the carboxy-terminal forkhead DNA-binding domain (Fig. 8c) . These results suggested that both the Runx1-binding site and forkhead DNA-binding domain are required for the suppressive effect of Foxp3 on IL-17 expression.
Having noted a functional interaction between RORgt and Runx1 and also between Foxp3 and RORgt, we next determined if RORgt and Runx1 physically interact with each other. We cotransfected 293T cells with Flag-tagged Runx1 (or Runx2 or Runx3) and Myc-tagged RORgt and immunoprecipitated cell lysates with anti-Myc or antiFlag. Flag-tagged Runx1 (or Runx2 and Runx3) and Myc-tagged RORgt were coimmunoprecipitated, even in the presence of the DNA intercalator ethidium bromide (Fig. 9a and Supplementary  Fig. 7 online) , which suggested that these two proteins interact in the absence of DNA. We then examined the interaction between endogenous RORgt and Runx1 in T H -17 cells. In the presence of ethidium bromide, anti-Runx1 coimmunoprecipitated RORgt from lysates of CD4 + cells cultured in T H -17-polarizing conditions (Fig. 9b) .
We next assessed the interaction between RORgt and wild-type versus mutant Foxp3. We cotransfected 293T cells with Flag-tagged Foxp3 and Myc-tagged RORgt then did reciprocal coimmunoprecipitation of cell lysates, followed by immunoblot analysis with anti-Flag and anti-Myc. RORgt and wild-type Foxp3 were coimmunoprecipitated (Fig. 9c) , which indicated a biochemical association between these two proteins. With a similar approach, we found that Flag-Foxp3 329VHL, as well as Flag-Foxp3D337 (a forkhead-truncated deletion mutant), still interacted with RORgt despite their substitutions and deletions (Fig. 9d) , even though these constructs did not inhibit IL-17 transcription (Fig. 8b) . This correlated with the functional data reported above suggesting that the ability of Foxp3 to inhibit IL-17 transcription is related to its interaction with Runx1 as well as RORgt ( Supplementary Fig. 8 online)
DISCUSSION
Here we have reported that Il17 transcription is governed by sequences present in the 2-kb promoter fragment upstream of the transcription start site, including sequences upstream of the RORgt-binding site. In addition, we have shown that Il17 transcription also depends on at least one conserved noncoding (enhancer) sequence (CNS-5) in the Il17 locus. These transcriptional control regions are involved in Il17 transcription, as they contain binding sites not only for RORgt but also for Runx1, which we found had a considerable potentiating effect on Il17 transcription. We found that Runx1 exerted no influence on Il17 transcription in the absence of RORgt and that Runx1 bound to RORgt during the course of T H -17 differentiation. In addition, we demonstrated that RORgt-and Runx1-induced IL-17 expression was inhibited by Foxp3 and that such inhibition required the binding of Foxp3 to Runx1. These findings allow us to propose that a complex three-way interaction among RORgt, Foxp3 and Runx1 is a chief regulator of the immune responses of both proinflammatory T H -17 cells and anti-inflammatory T reg cells.
As mentioned above, extensive data from reporter assays showed that transcriptional control through the 2-kb promoter required the influence of at least one distant enhancer site for maximum IL-17 expression. It is well known that such promoter-enhancer communication could occur through the interaction of proteins binding to each of these elements, which then leads to the 'looping out' of intervening DNA and the creation of a promoter-enhancer 'holocomplex' . This 'holocomplex' could then maintain a high local concentration of transcription factors and establish a favorable environment at the promoter that facilitates maximum gene transcription 25 . This seemed to be true in the case of Il17 transcription, as mutation of the RORgt-binding site in the promoter or the enhancer resulted in much less Il17 transcription and because RORgt and Runx1, which bind to promoter, also bound to the enhancer; in addition, coimmmunoprecipitation studies indicated that RORgt and Runx1 underwent direct physical interaction in developing T H -17 cells.
One of the important aspects of Runx1 transcriptional activity in terms of IL-17 expression is its absolute dependence on the presence 23 , a cytokine whose signaling has been shown to be related to Runx family members [20] [21] [22] . The Runx family of transcription factors consists of three highly homologous proteins, each containing a very similar 'runt' DNAbinding site [27] [28] [29] [30] . Given that all three family members are expressed in T H -17 cells, we did several studies to determine which members were involved in Il17 transcription. We found that silencing of Runx1 expression strongly suppressed IL-17 expression, whereas silencing of Runx2 had a marginal effect and silencing of Runx3 almost no effect. Those results correlated with the results of studies in which we overexpressed the various Runx family members in T H -17 or T H 0 cells either alone or with RORgt. In these studies, Runx2 had a considerable capacity to upregulate RORgt-induced IL-17 expression, whereas Runx3 had only a marginal effect most evident when RORgt was also overexpressed in T H 17 conditions. We therefore conclude that Runx1 is the main Runx family member involved in T H -17 development and that Runx2 may also be involved but to a considerably lesser extent than Runx1; Runx3, in contrast, seems to have little or no involvement in IL-17 expression. In cells in which Runx and RORgt were overexpressed, we found that Runx2 and Runx3, as well as Runx1, physically interacted with RORgt in coimmunoprecipitation studies; thus, either such binding is nonphysiological or Runx activity in terms of IL-17 transcription involves more than Runx1 binding. Further studies of the function of Runx family members in Il17 transcription should use gene-targeted mice deficient in one or more Runx family member(s).
Our data add greater complexity to the understanding of the molecular basis of the reciprocal relation between T H -17 and T reg differentiation. It is now apparent that Runx1 must be included in the 'mix' of factors that regulate such differentiation. We have shown here that RORgt bound to both Foxp3 and Runx1, and published work has demonstrated that Foxp3 and Runx1 interact 16 . These interactions 'set the stage' to allow shifting of the direction of T cell differentiation according to extracellular and environmental conditions. Thus, in cells stimulated only by TGF-b (as in T reg cellpolarizing conditions), Foxp3 is produced in relatively large amounts and the main pathway is probably characterized by the interaction of Foxp3 with both Runx1 and RORgt. In these conditions, Foxp3 inhibits RORgt-mediated IL-17 transcription either directly in the form of a Foxp3-Runx1 complex or indirectly by blocking the ability of Runx1 to enhance RORgt-mediated Il17 transcription. That view is supported by the finding that overexpression of Foxp3 329VHL, the Foxp3 mutant with an impaired ability to interact with Runx1, did not inhibit RORgt-induced IL-17 expression, even though it was still able to bind to RORgt. In contrast, in cells stimulated in the presence of TGF-b and IL-6 or IL-21 (as in T H -17 conditions), Foxp3 synthesis is inhibited 24, 31 , and the main pathway is probably the binding of Runx1 to RORgt and subsequent enhancement of Il17 transcription. Finally, Runx-mediated transcription has been shown to be context dependent, which means that Runx factors recruit other transcription factors and these complexes act together to induce promoter activation or repression. Given published work showing that Foxp3 functions in tandem with the transcription factor NFAT 27, 32 , it is possible that interactions between Runx1 and Foxp3 and those between Runx1 and RORgt also involve a higher order of transcription factor assembly including NFAT.
The essential role of Runx1 in Foxp3 function 16 and T reg cell development, as well as in RORgt function and IL-17 expression, as shown here, provides a possible basis for the finding that singlenucleotide polymorphisms affecting the consensus binding site for Runx1, or Runx1 itself, are associated with susceptibility to several autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis and psoriasis [33] [34] [35] . It seems reasonable to suspect these genetic abnormalities influence susceptibility because they might cause changes in Runx1 function that 'tip the balance' between regulatory and effector cells in favor of effector cells. Thus, understanding the molecular basis of the interaction of Runx1, RORgt and Foxp3 in the development of T reg and T H -17 cells may provide insight into clinical immune pathologies.
METHODS
Mice. BALB/c mice 8-12 weeks of age (Jackson Laboratories) were maintained in specific pathogen-free conditions. Studies followed a protocol approved by the Animal Care and Use Committee of the National Institute of Allergy and Infectious Diseases. Plasmids. The Flag-Runx1-mouse stem cell virus (MSCV) retroviral vector and pCMV-Tag2-Foxp3 plasmid were provided by M. Ono 16 . The Myc-RORgt-GFP-S-003 plasmid was provided by S. Kersh 26 . Full-length wild-type Foxp3 cDNA and the Foxp3 mutant constructs were amplified by PCR and were cloned into MSCV-IRES-Thy-1.1 (MIT) retroviral vector. The Foxp3 329VHL construct was made with the Quickchange II site-directed mutagenesis kit (Stratagene). Thy-1.1-RORgt was made by cloning of the RORgt fragment released from RORgt-human CD2-MSCV provided by Y. He 36 into the MSCV-Thy-1.1 vector.
Promoter and CNS promoter reporter constructs. The 0.6-kb, 1.1-kb and 2-kb fragments of the Il17 proximal promoter were obtained by PCR with mouse genomic DNA as template. The PCR products were cloned into the pGL4.10 basic luciferase vector (Promega) through the use of the NheI and BglII entry sites. CNS elements were generated by PCR, then were ligated into upstream of the 2-kb, 1.1-kb or 0.6-kb promoter fragments in the pGL4.10 luciferase vector. Mutations in the promoter and CNS were introduced with the Quickchange II site-directed mutagenesis kit (Stratagene; PCR primers, Supplementary Table 1 online). All constructs were verified by sequencing.
Luciferase reporter assay. Jurkat cells were transfected with a Nucleofector II (Amaxa). In a typical study, 3 Â 10 6 cells in 100 ml Amaxa solution V were transfected with 2 mg luciferase reporter construct and 0.1 mg pRL-TK plasmid along with 2 mg plasmid encoding RORgt or Runx1 or control plasmid. Transfected cells were incubated overnight, then were stimulated for 6 h with 20 nM PMA (phorbol 12-myristate 13-acetate) and 2 mM ionomycin. Cells were lysed and luciferase activity was measured with a dual luciferase assay system (Promega). Each transfection was done in triplicate.
Retroviral transduction and intracellular staining. For the production of ecotropic retroviruses, Phoenix cells were transfected by Lipofectamine 2000 (52887; Invitrogen) with retroviral constructs (20 mg for single-plasmid transfection and 10 mg each for double-plasmid transfection, per 10-cm plate), and 48 h after transfection, virus supernatants were collected and were filtered through 0.45-mm low-protein-binding membranes. For transduction of virus, naive CD4 + cells were first isolated by negative selection, then were positively selected with CD62L magnetic beads (Miltenyi) and were cultured for 16-24 h at a density of 1 Â 10 6 cells per well in nonpolarizing conditions (no added cytokines) in wells precoated with anti-CD3 (2C11; 2 mg/ml; BD Biosciences) and anti-CD28 (37.51; 1 mg/ml; BD Biosciences). These activated cells were then transduced with retrovirus supernatant by centrifugation for 1 h at 2,000g in the presence of polybrene (8 mg/ml; Sigma). After removal of the virus-containing supernatants, cells were recultured in T H 0 conditions (no cytokines and no antibody) or T H -17-polarizing conditions (10 ng/ml of IL-6 (406ML) plus 2.5 ng/ml of TGF-b (240-B); R&D systems) or other conditions. The next day, cells were again transduced with retrovirus supernatant and recultured as before. After 4 d of culture, cells were restimulated for 5 h with 20 nM PMA (Sigma) and 1 mM ionomycin with the addition of GolgiStop (BD Bioscience) during the final 3 h. Intracellular staining and flow cytometry were then done as described 37 .
RNA-mediated interference. For knockdown of Runx1, Runx2 or Runx3, CD4 + T cells were purified with the CD4 Pan T Cell Isolation kit (Miltenyi) and were directly transfected by nucleofection with siRNA specific for Runx1, Runx2 or Runx3, respectively (all from Dharmacon; predesigned ON-TARGETplus SMARTpool siRNA) or 'scrambled' control siRNA (Dhamacon). For transfection, 2 Â 10 6 cells in 100 ml mouse T cell Nucleofector solution (Amaxa) were transfected with 300 pmol total of siRNA with the X-001 program (Amaxa). After transfection, cells were incubated for 4 h at 37 1C, then were activated with anti-CD3 (2 mg/ml) and anti-CD28 (1 mg/ml) and were cultured in T H -17-polarizing condition as described above. After 48 h of activation, some transfected cells were collected and RNA was made; RNA was then analyzed by real-time RT-PCR. After a total of 72 h of activation, the remaining cells were allowed to 'rest' for another 48 h and then were restimulated with PMA and ionomycin, and IL-17 production was measured as described above. For Runx1 shRNA knockdown, double-stranded DNA short hairpin sequence targeting the coding region of Runx1 (5¢-ATCACTGGCGCTGCAACAAGAC-3¢) or control shRNA (5¢-AATGAAGAT-CAAGATCATTGCG-3¢) was cloned into the MSCV-LTRmiR30-PIG (LMP) retroviral vector (Openbiosystems), which encodes GFP and a puromycin selection marker, according to the manufacturer's instruction. Retroviral production and transduction was done as described above. After 4 d of culture, cells were restimulated for 5 h with PMA and ionomycin with GolgiStop added during the final 3 h. Intracellular staining was then done as described 37 . For transduction of the mouse lymphoma EL4 cell line, 1 Â 10 6 cells were transduced with retroviral supernatant containing either control shRNA or Runx1-specific shRNA as described above, then puromycin (5 mg/ml) was added to the culture medium immediately after transduction. GFP + cells were identified by flow cytometry, cells were collected and RNA was made after over 90% of the cells were GFP + .
Corrigendum: Interactions among the transcription factors Runx1, RORγt and Foxp3 regulate the differentiation of interleukin 17-producing T cells In the version of this article initially published, two panels in Figure 9a were horizontally inverted. The error has been corrected in the HTML and PDF versions of the article.
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